Skip to main content
Premium Trial:

Request an Annual Quote

Celera Genomics Reports Dwindling Revenues, Narrowed Loss for Q3 of FY2004

NEW YORK, April 27 (GenomeWeb News) - Celera Genomics' revenues fell sharply while its losses narrowed during the fiscal year 2004 third quarter, the company said today.


Revenues for the quarter decreased to $11.2 million, from $20.3 million during the same quarter last year. Celera attributed most of this decrease to expiring customer agreements.


Celera's R&D spending was $28.3 million, up from $27 million during the year-ago period.


The company's net loss for the quarter narrowed to $21.9 million, or $.3 per share, from $26.7 million, or $.37 per share, during the same period last year.


As of March 31, Celera Genomics, a unit of Applera, had $739 million in cash and short-term investments.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.